Accelerate Diagnostics Inc (OQ:AXDX)

Business Focus: Advanced Medical Equipment & Technology

May 08, 2024 04:42 pm ET
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results
TUCSON, Ariz., May 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.
May 02, 2024 09:30 am ET
Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.
TUCSON, Ariz., May 2, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to review 2024 first quarter results.
Mar 28, 2024 04:05 pm ET
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
TUCSON, Ariz., March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
Jan 19, 2024 08:20 am ET
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
TUCSON, Ariz., Jan. 19, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock. The public offering price for each unit is $1.50 and the public offering price for each pre-funded unit
Jan 16, 2024 06:45 am ET
Accelerate Diagnostics Announces Launch of Proposed Public Offering
TUCSON, Ariz., Jan. 16, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exc
Jan 07, 2024 07:00 pm ET
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
TUCSON, Ariz., Jan. 7, 2024 /PRNewswire/ --  Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023.
Nov 27, 2023 08:15 am ET
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
Working together to bring rapid, automated microbial identification directly from positive blood culture samples
Nov 09, 2023 03:05 pm ET
Accelerate Diagnostics Reports Third Quarter 2023 Results
TUCSON, Ariz., Nov. 9, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023.
Oct 30, 2023 09:30 am ET
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
TUCSON, Ariz., Oct. 30, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time to review 2023 third quarter results.
Jul 27, 2023 09:30 am ET
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
TUCSON, Ariz., July 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time to review 2023 second quarter results.
Jul 10, 2023 09:00 am ET
Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split
TUCSON, Ariz., July 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on July 11, 2023. The Company's common stock will begin trading on a post-split basis at the market open on July 12, 2023, under the Company's existing trading symbol "AXDX". The reverse stock split is part of the Company's plan to regain
Jun 13, 2023 09:00 am ET
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
TUCSON, Ariz., June 13, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement. Through a series of transactions, the company has simplified its capital structure, extended-out its debt maturity 3.5 years and secured $24 million of new funding, providing opportunities for future growth and innovation.
May 11, 2023 04:05 pm ET
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
TUCSON, Ariz., May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.
Apr 27, 2023 09:30 am ET
Accelerate Diagnostics scheduled call to review 2023 first quarter results
TUCSON, Ariz., April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time to review 2023 first quarter results.
Mar 29, 2023 04:05 pm ET
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
TUCSON, Ariz., March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.
Mar 15, 2023 09:30 am ET
Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results
TUCSON, Ariz., March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m. Eastern Time to review 2022 fourth quarter and full year results.
Mar 14, 2023 08:00 pm ET
Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement
TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023.
Mar 08, 2023 07:30 am ET
Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors
TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023.
Dec 19, 2022 12:32 pm ET
Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit
TUCSON, Ariz., Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit. Included in the submission are additional escalation and de-escalation agents for Gram-negative organisms, additional antibiotics for Acinetobacter baumannii, and breakpoint updates. These updates add oral de-escalation antibiotic options for clinicians to use, which can assist with expediting patient discharge plans.
Nov 16, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Veru and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (NASDAQ: AXDX), and Veru Inc. (NASDAQ: VERU). Our investigations concern whether these...
Nov 14, 2022 03:05 pm ET
Accelerate Diagnostics Reports Third Quarter 2022 Financial Results
TUCSON, Ariz., Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022.
Nov 14, 2022 01:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate" or the "Company") (NASDAQ: AXDX).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Nov 11, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Establishment, Accelerate Diagnostics, Instil and Unisys and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Establishment Labs Holdings Inc. (NASDAQ: ESTA), Accelerate Diagnostics, Inc. (NASDAQ: AXDX), Instil Bio, Inc. (NASDAQ:...
Nov 07, 2022 04:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX
Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ: AXDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Nov 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Instil and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (NASDAQ: AXDX), and Instil Bio, Inc. (NASDAQ: TIL). Our investigations concern whether these...
Nov 04, 2022 03:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX
NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate" or the "Company") (NASDAQ: AXDX).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Oct 31, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Establishment, FIGS, and Accelerate Diagnostics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Establishment Labs Holdings Inc. (NASDAQ: ESTA), FIGS, Inc. (NYSE: FIGS), and Accelerate Diagnostics, Inc. (NASDAQ: AXDX)....
Oct 31, 2022 05:22 pm ET
ROSEN, A TOP RANKED FIRM, Encourages Accelerate Diagnostics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – AXDX
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) resulting from allegations that Accelerate Diagnostics may...
Oct 27, 2022 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ:
Oct 26, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Establishment, FIGS, and Accelerate Diagnostics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Establishment Labs Holdings Inc. (NASDAQ: ESTA), FIGS, Inc. (NYSE: FIGS), and Accelerate Diagnostics, Inc. (NASDAQ: AXDX)....
Oct 26, 2022 05:01 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ: AXDX) investors concerning the Company’s possible violations of federal securities laws.
Oct 26, 2022 02:52 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ:
Oct 25, 2022 09:00 pm ET
ACCELERATE DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Accelerate Diagnostics, Inc. on Behalf of Accelerate Diagnostics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or the “Company”) (NASDAQ: AXDX) on behalf of Accelerate Diagnostics stockholders. Our investigation concerns whether Accelerate Diagnostics has violated the federal securities laws and/or engaged in other unlawful business practices.
Oct 25, 2022 09:59 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or “the Company”) (NASDAQ:
Oct 25, 2022 06:19 am ET
Accelerate Diagnostics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Accelerate Diagnostics, Inc. (NASDAQ: AXDX) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Accelerate Diagnostics stock. Accelerate Diagnostics investors are...
Oct 24, 2022 02:33 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Accelerate Diagnostics, Inc. Investors to Inquire About Securities Class Action Investigation – AXDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) resulting from allegations that Accelerate Diagnostics may have issued materially misleading business information to the investing public.
Oct 24, 2022 01:19 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or “the Company”) (NASDAQ:
Oct 24, 2022 12:40 pm ET
Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost money in their Accelerate Diagnostics, Inc. investment should contact the firm to learn more about how...
Oct 24, 2022 10:02 am ET
Accelerate Diagnostics scheduled call to review 2022 third quarter results
TUCSON, Ariz., Oct. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m. Eastern Time to review 2022 third quarter results.
Aug 18, 2022 09:30 pm ET
Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
TUCSON, Ariz., Aug. 18, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds to Accelerate Diagnostics from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $35.0 million. In addition, Accelerate Diagnostics has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its commo
Aug 17, 2022 06:00 pm ET
Accelerate Diagnostics Announces Proposed Public Offering of Common Stock
TUCSON, Ariz., Aug. 17, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced that it has commenced an underwritten public offering of shares of its common stock. Accelerate Diagnostics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discounts and commissions. Accelerate Diagnostics anticipates using the net proceeds from the offering for general corporate purposes and to fund commercialization ef
Aug 15, 2022 08:15 am ET
Accelerate Diagnostics Reports Second Quarter 2022 Financial Results
TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.
Aug 15, 2022 06:50 am ET
BD, Accelerate Diagnostics Announce Global Commercial Collaboration
Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide
Jul 25, 2022 09:30 am ET
Accelerate Diagnostics scheduled call to review 2022 second quarter results
TUCSON, Ariz., July 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m. Eastern Time to review 2022 second quarter results.
Jul 11, 2022 08:00 am ET
Accelerate Diagnostics announces commercialization in Europe of its Accelerate Arc™ system having completed IVDR registration
- Commercialization of the Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial identification (ID) for positive blood cultures across the large installed base of MALDI system users.
Jun 27, 2022 09:31 am ET
Thinking about buying stock in Neurosense Therapeutics, Boxed, Snap, RealReal, or Accelerate Diagnostics?
NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRSN, BOXD, SNAP, REAL, and AXDX.
Jun 23, 2022 09:31 am ET
Thinking about buying stock in Li Auto, F-Star Therapeutics, Geovax Labs, Accelerate Diagnostics, or Funko?
NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LI, FSTX, GOVX, AXDX, and FNKO.
May 23, 2022 09:30 am ET
Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022
TUCSON, Ariz., May 23, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 7, 2022, at 10:00 AM Central Time.
May 16, 2022 04:05 pm ET
Accelerate Diagnostics Reports First Quarter 2022 Financial Results
TUCSON, Ariz., May 16, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2022.
May 16, 2022 08:06 am ET
Accelerate Diagnostics announces commercialization of its Accelerate Arc™ system having completed IVD registration with FDA
Commercialization of Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial ID for positive blood cultures across the large installed base of MALDI system users. The Accelerate Arc system can cut hours of wait time, eliminate laborious hands-on sample prep, and offer significant cost savings for healthcare facilities compared to current methods.
Apr 29, 2022 09:30 am ET
Accelerate Diagnostics scheduled call to review 2022 first quarter results.
TUCSON , April 29, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, May 16, 2022, at 4:30 p.m. Eastern Time to review 2022 first quarter results.
Apr 25, 2022 08:41 am ET
Accelerate Diagnostics Presents New Data at ECCMID 2022 Demonstrating Rapid and Accurate Results Using Automated Accelerate Arc™ Module and BC Kit
New data shows the Accelerate Arc System enables automated and rapid sample preparation that yields robust reportability and accurate microbial identification for positive blood cultures using MALDI when compared to conventional MALDI methodsTUCSON, Ariz., April 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the release of new data on the Accelerate Arc Module and BC kit at the 32nd European Congress for Clinical Microbiology an
Mar 28, 2022 08:05 am ET
Accelerate Diagnostics Announces Launch Of Accelerate Arc™ Module and BC Kit
The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) resultsUnlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system usersTUCSON, Ariz., March 28, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identificatio
Mar 08, 2022 03:05 pm ET
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2021 Financial Results
TUCSON, Ariz., March 8, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021.
Feb 24, 2022 08:30 am ET
Accelerate Diagnostics scheduled call to review 2021 fourth quarter and full year results
TUCSON, Ariz., Feb. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 8, 2022, at 4:30 p.m. Eastern Time to review 2021 fourth quarter and full year financial results.
Feb 02, 2022 08:30 am ET
Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time
TUCSON, Ariz., Feb. 2, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time.
Jan 13, 2022 08:15 am ET
Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results
TUCSON, Ariz., Jan. 13, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021. Highlights for the fourth quarter and full-year 2021 are presented below.
Jan 12, 2022 08:15 am ET
Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts
TUCSON, Ariz., Jan. 12, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for the Company's Accelerate Pheno® System.
Dec 29, 2021 08:30 am ET
Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022
TUCSON, Ariz., Dec. 29, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern.
Nov 22, 2021 06:00 am ET
New Accelerate Pheno® System Multi-Center Study Published in Clinical Infectious Diseases
TUCSON, Ariz., Nov. 22, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases. The multi-center, real-world study compared data before and after implementation of the Accelerate Pheno system across several hospitals to determine its impact on the treatment of patients with bloodstream infections. The data showed statistically significant reductions in time to optimal antimicrobial therapy, modification, and de-escalations associated with wid
Nov 09, 2021 03:05 pm ET
Accelerate Diagnostics Reports Third Quarter 2021 Financial Results
TUCSON, Ariz., Nov. 9, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing adjustments.
Oct 19, 2021 08:00 am ET
Accelerate Diagnostics Schedules Call to Review 3rd Quarter 2021 Results
TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m. Eastern Time to review 2021 third quarter financial results.
Sep 23, 2021 09:15 am ET
Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock
TUCSON, Ariz., Sept. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2023 (the "Notes"). Under the terms of these exchange agreements:
Aug 05, 2021 04:05 pm ET
Accelerate Diagnostics Reports Second Quarter 2021 Financial Results
TUCSON, Ariz., Aug. 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021.
Aug 03, 2021 08:00 am ET
Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems
TUCSON, Ariz., Aug. 3, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the new IVD configuration of its Accelerate PhenoTest® BC kit has been CE marked and is ready for use in Europe.
Jul 15, 2021 08:00 am ET
Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results
TUCSON, Ariz., July 15, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time to review 2021 second quarter financial results.
Jul 07, 2021 08:00 am ET
Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States
TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States. With this launch, the Company now provides two solutions for fast sepsis testing.
Jun 30, 2021 10:05 am ET
New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
TUCSON, Ariz., June 30, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021. The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections.
Feb 23, 2021 03:15 pm ET
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results
TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020.
Feb 01, 2021 07:00 am ET
Accelerate Diagnostics schedules call to review 2020 fourth quarter and full year results
TUCSON, Ariz., Feb. 1, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Tuesday, February 23, 2021, at 4:30 p.m. Eastern Time to review 2020 fourth quarter and full year financial results.
Feb 01, 2021 07:00 am ET
Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time
TUCSON, Ariz., Feb. 1, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time.
Jan 27, 2021 07:30 am ET
Thinking about buying stock in AMC Entertainment, GameStop, Express, Accelerate Diagnostics, or Remark Holdings?
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, GME, EXPR, AXDX, and MARK.
Jan 12, 2021 05:00 am ET
Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below.
Nov 05, 2020 03:29 pm ET
Accelerate Diagnostics Reports Third Quarter 2020 Financial Results
TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020.
Aug 06, 2020 04:15 pm ET
Accelerate Diagnostics Reports Second Quarter 2020 Financial Results & Announces New Product Offering
TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2020.
Jul 16, 2020 08:00 am ET
Accelerate Diagnostics Schedules Call to Review Second Quarter 2020 Results
TUCSON, Ariz., July 16, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern Time to review 2020 second quarter financial results.
Jun 15, 2020 09:20 am ET
Faruqi & Faruqi, LLP is Investigating Accelerate Diagnostics, Inc. (AXDX) on Behalf of its Shareholders
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or the “Company”) (NASDAQ: AXDX). The investigation focuses on whether the Company’s...
May 07, 2020 04:01 pm ET
Accelerate Diagnostics Announces First Quarter Financial Results and Provides COVID-19 Business Updates
TUCSON, Ariz., May 7, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced financial results for the quarter ending March 31, 2020 and provided a business update regarding the impact of the ongoing COVID-19 pandemic on the Company's operations.
Apr 15, 2020 05:08 pm ET
Accelerate Diagnostics Announces Preliminary First Quarter Financial Results and Provides COVID-19 Business Updates; Schedules First Quarter 2020 Financial Results Conference Call for May 7, 2020
TUCSON, Ariz., April 15, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending March 31, 2020 and provided a business update regarding the impact of the ongoing COVID-19 pandemic on the Company's operations. The Company also announced that it will report full results for the quarter ending March 31, 2020 after the market close on Thursday, May 7, 2020.
Apr 15, 2020 05:07 pm ET
Accelerate Diagnostics and BioCheck Announce Commercial Supply and Collaboration Agreement to Distribute MS-FAST Chemiluminescence Immunoassay Analyzer and SARS-CoV-2 Antibody Tests
TUCSON, Ariz., April 15, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that they have entered into a commercial supply and collaboration agreement. Under the agreement, Accelerate Diagnostics will distribute the BioCheck MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck's SARS-CoV-2 tests for the detection of IgG and IgM antibodies. The agreement covers North America, Europe and the Middle East.
Nov 07, 2019 03:01 pm ET
Accelerate Diagnostics Reports Third Quarter 2019 Financial Results
TUCSON, Ariz., Nov. 7, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2019.
Nov 04, 2019 06:45 am ET
Accelerate Diagnostics Appoints Roland Diggelmann to its Board of Directors
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors.
Oct 17, 2019 08:00 am ET
Accelerate Diagnostics Schedules Call to Review Third Quarter 2019 Results
TUCSON, Ariz., Oct. 17, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that it will report financial results for the third quarter of 2019 after the market close on Thursday, November 7, 2019. The company's management will host a conference call at 4:30 p.m. ET that same day to review the results.
Oct 03, 2019 08:00 am ET
Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that were first reported in the Company's September 18, 2019 press release.
Sep 18, 2019 07:30 am ET
Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies
TUCSON, Ariz., Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019.
Aug 08, 2019 04:06 pm ET
Accelerate Diagnostics Names Jack Phillips Chief Operating Officer
TUCSON, Ariz., Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Jack Phillips has been appointed Chief Operating Officer.  Mr. Phillips joins Accelerate from Roche Diagnostics, the world's leading diagnostics company.
Aug 08, 2019 04:01 pm ET
Accelerate Diagnostics Reports Second Quarter 2019 Financial Results
TUCSON, Ariz., Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2019.
Jul 08, 2019 08:30 am ET
Accelerate Diagnostics Schedules Call to Review Second Quarter 2019 Results
TUCSON, Ariz., July 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that it will report financial results for the second quarter of 2019 after the market close on Thursday, August 8, 2019. The company's management will host a conference call at 4:30 p.m. ET that same day to review the results.
May 24, 2019 12:45 pm ET
Accelerate Diagnostics to Present at the William Blair Growth Stock Conference on June 6, 2019
TUCSON, Ariz., May 24, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Chief Executive Officer, Larry Mehren, and Chief Financial Officer, Steve Reichling will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019 at 12:00 p.m. Central Time.
May 09, 2019 04:01 pm ET
Accelerate Diagnostics Reports First Quarter 2019 Financial Results
TUCSON, Ariz., May 9, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter ended March 31, 2019.
Apr 26, 2019 11:44 am ET
Accelerate Diagnostics Schedules Call to Review First Quarter 2019 Results
TUCSON, Ariz., April 26, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that it will report financial results for the first quarter of 2019 after the market close on Thursday, May 9, 2019. The Company's management will host a conference call at 4:30 p.m. ET that same day to review the results.
Mar 08, 2019 02:38 pm ET
Accelerate Diagnostics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
TUCSON, Ariz., March 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 8:40 AM Eastern Time.
Feb 19, 2019 03:01 pm ET
Accelerate Diagnostics Reports 2018 Fourth Quarter and Full-Year Financial Results
TUCSON, Ariz., Feb. 19, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced financial results for the fourth quarter and fiscal year ended December 31, 2018. 
Feb 08, 2019 07:50 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within New Relic, Clean Harbors, Sage Therapeutics, Accelerate Diagnostics, Fortinet, and Colfax — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of New Relic, Inc. (NYSE:NEWR), Clean Harbors, Inc. (NYSE:CLH), Sage...
Feb 05, 2019 03:03 pm ET
Accelerate Diagnostics schedules call to review 2018 fourth quarter and full-year results
TUCSON, Ariz., Feb. 5, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, February 19, 2019 at 4:30 p.m. Eastern Time to review 2018 fourth quarter and full-year financial results.
Jan 02, 2019 03:48 pm ET
Accelerate Diagnostics to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
TUCSON, Ariz., Jan. 2, 2019 /PRNewswire/ -- Accelerate Diagnostics announced today that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019, at 2:30 PM Pacific Time.
Nov 27, 2018 06:12 am ET
Accelerate Diagnostics Pledges Matching Support for Sepsis Alliance #GivingTuesday Movement to Raise Awareness of Sepsis as a Medical Emergency
TUCSON, Ariz., Nov. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. has joined with Sepsis Alliance to celebrate #GivingTuesday, November 27th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide.
Nov 09, 2018 07:45 am ET
Analysis: Positioning to Benefit within CSS Industries, Accelerate Diagnostics, Oasis Petroleum, Model N, Carbonite, and Masonite International — Research Highlights Growth, Revenue, and Consolidated
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CSS Industries, Inc. (NYSE:CSS), Accelerate Diagnostics, Inc....
Nov 06, 2018 03:01 pm ET
Accelerate Diagnostics reports Q3 2018 financial results
TUCSON, Ariz., Nov. 6, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018.  The company reported a 40% increase in U.S. instruments placed under commercial contract, and revenue for the quarter of $1.3 million, an increase of 64% from the prior year quarter. Worldwide, revenue-generating instruments combined with those under evaluation agreements grew to 458 instruments.
Oct 17, 2018 04:51 pm ET
Accelerate Diagnostics to Review Third Quarter 2018 Results on November 6th
TUCSON, Ariz., Oct. 17, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it will host a conference call on Tuesday, November 6, 2018 to review the company's third quarter 2018 financial results and commercial progress.
Oct 15, 2018 09:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Meritor, Fred's, Arena Pharmaceuticals, AMERISAFE, Accelerate Diagnostics, and NextEra Energy — New Research Emphasizes Economic Gro
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Meritor, Inc. (NYSE:MTOR), Fred's, Inc. (NASDAQ:FRED), Arena...
Sep 27, 2018 04:01 pm ET
Accelerate Diagnostics announces resignation of Joan Martin as Head of Europe, Middle East, and Africa
TUCSON, Ariz., Sept. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that Joan Martin resigned from his position as Executive Vice President and Head of Europe, Middle East, and Africa and will be leaving the company for personal reasons.
Aug 08, 2018 07:45 am ET
Report: Developing Opportunities within CMS Energy, International Paper, IBERIABANK, Accelerate Diagnostics, El Paso Electric, and FTI Consulting — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CMS Energy Corporation (NYSE:CMS), International Paper Company (NYSE:IP),...
Aug 07, 2018 07:50 am ET
Accelerate Diagnostics Receives New Innovative Technology Contract from Vizient for the Accelerate Pheno™ System
TUCSON, Ariz., Aug. 7, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States. The contract was based on a recommendation of the Accelerate Pheno™ system by hospital experts in this category who serve on one of Vizient's member-led councils.  Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization's care de
Aug 06, 2018 04:01 pm ET
Accelerate Diagnostics reports Q2 2018 financial results
TUCSON, Ariz., Aug. 6, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30, 2018.  The company posted revenue of $1.7 million, up 142% from the prior year quarter, and reported a record number of new agreements signed in the quarter bringing the global total to 430 instruments. Contracts for customer evaluations total 312 instruments while commercial placements grew to 118 across the U.S., European, and Middle East regions.
Jul 19, 2018 02:30 pm ET
Accelerate Diagnostics to Review Second Quarter 2018 Results on August 6th
Accelerate Diagnostics, Inc. announced today it will host a conference call on Monday, August 6, 2018 to review the company’s second quarter 2018 financial results and commercial progress. President and Chief Executive Officer, Lawrence Mehren,...
Jun 05, 2018 11:30 am ET
Accelerate Diagnostics to Present at the William Blair 38th Annual Growth Stock Conference
Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer is scheduled to speak at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois on Wednesday, June 13, 2018 at 2:40 PM,...
May 09, 2018 04:03 pm ET
Accelerate Diagnostics reports Q1 2018 financial results
Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018.  The company generated revenue of $801,000, up 51% from the prior year, and reported signed agreements for 345 instruments. Contracts for customer...
May 04, 2018 07:35 am ET
Report: Developing Opportunities within US Ecology, Universal Health Realty Income Trust, Accelerate Diagnostics, Chesapeake Lodging Trust, Super Micro Computer, and Choice Hotels International — Futu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US Ecology, Inc. (NASDAQ:ECOL), Universal Health Realty Income Trust...
Apr 30, 2018 10:42 am ET
Accelerate Diagnostics to Review First Quarter 2018 Results on May 9th
TUCSON, Ariz., April 30, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will host a conference call on Wednesday, May 9, 2018 to review its first quarter 2018 financial results and commercial progress.
Apr 21, 2018 03:37 am ET
Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018
Four integrated symposium sessions, 11 poster presentations, and case studies will cover the clinical value of integrating diagnostic stewardship into current sepsis protocols given the rising rates of antibiotic resistance
Mar 23, 2018 02:15 am ET
Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering
TUCSON, Ariz., March 23, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“Accelerate Diagnostics”) (NASDAQ:AXDX) today announced the pricing of $150.0 million aggregate principal amount of 2.50% convertible senior notes due 2023 (the “notes”) in a private placement to...
Mar 22, 2018 07:08 am ET
Accelerate Diagnostics Inc. Announces $150 Million Convertible Notes Offering
TUCSON, Ariz., March 22, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced its intention to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of convertible senior notes due 2023 (the “notes”)...
Mar 02, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide — New Horizons, Emerging Trends, and Upcoming
NEW YORK, March 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accelerate Diagnostics, Inc. (NASDAQ:AXDX), FTI Consulting,...
Feb 15, 2018 04:05 pm ET
Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
TUCSON, Ariz., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for Q4 of $2.1 million, doubling revenue for the...
Feb 08, 2018 05:25 pm ET
Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018
TUCSON, Ariz., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. will host a conference call on Thursday, February 15, 2018 to review its fourth quarter and full-year financial results for 2017.
Jan 10, 2018 07:57 am ET
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
TUCSON, Ariz., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of its latest assay for the Accelerate Pheno™ system targeting...
Jan 08, 2018 07:40 am ET
New Research Coverage Highlights ConnectOne, Rockwell Medical, Accelerate Diagnostics, Eleven Biotherapeutics, Renasant, and Natera — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Jan. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConnectOne Bancorp, Inc. (NASDAQ:CNOB), Rockwell Medical,...
Jan 04, 2018 01:44 pm ET
Accelerate Diagnostics to Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco
TUCSON, Ariz., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer is scheduled to speak at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation...
Nov 27, 2017 06:27 pm ET
Accelerate Diagnostics Joins Sepsis Alliance in Global #GivingTuesday Movement to Raise Awareness of Sepsis as Medical Emergency
TUCSON, Ariz., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. has teamed up with Sepsis Alliance for #GivingTuesday, November 28th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage...
Nov 16, 2017 12:06 pm ET
Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors
TUCSON, Ariz., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced the election of Charles Watts, M.D. to the company’s board of directors. His appointment is effective November 14, 2017.
Nov 15, 2017 08:30 am ET
Accelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare Conference in New York City
TUCSON, Ariz., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Lawrence Mehren, president and chief executive officer of Accelerate Diagnostics, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28,...
Nov 02, 2017 04:01 pm ET
Accelerate Diagnostics reports Q3 2017 financial results
TUCSON, Ariz., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017.  The company further reported signed agreements for 295 instruments year to date; contracts for customer...
Jul 18, 2017 05:38 pm ET
Accelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd
TUCSON, Ariz., July 18, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will host a conference call on Thursday, August 3, 2017 to discuss its second quarter 2017 financial results and commercial progress....
Jun 07, 2017 06:06 pm ET
Accelerate Diagnostics to Present at the 37th Annual Growth Stock Conference hosted by William Blair & Company
TUCSON, Ariz., June 07, 2017 (GLOBE NEWSWIRE) -- Lawrence Mehren, president and chief executive officer of Accelerate Diagnostics, will present at the 37th Annual Growth Stock Conference hosted by William Blair & Company in Chicago on Wednesday, June 14, 2017, at 04:00 PM Central Time....
May 15, 2017 05:14 pm ET
Accelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering
TUCSON, Ariz., May 15, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company. In addition, Accelerate Di...
May 09, 2017 09:59 pm ET
Accelerate Diagnostics Announces Pricing of Upsized Public Offering of Common Stock
TUCSON, Ariz., May 09, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock, upsized from the original share offering of 2,500,000 shares of common stock, at a price to the public of $28.85 per share. All of the shares are being sold by Accelerate Diagnostics. The gross proceeds to Accelerate Diagnostics from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $79.3 million. The offering...
May 08, 2017 04:14 pm ET
Accelerate Diagnostics Announces Proposed Public Offering of Common Stock
TUCSON, Ariz., May 08, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance...
May 03, 2017 04:05 pm ET
Accelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017
TUCSON, Ariz., May 03, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending March 31, 2017 including signed customer evaluation contracts covering 169 instruments, 22 additional instruments converted into revenue generating placements, and revenue growth exceeding 325% of the same period in the prior year....
Feb 23, 2017 09:45 pm ET
Accelerate Diagnostics Receives FDA Marketing Authorization for the Accelerate Pheno™ System and Accelerate PhenoTest™ BC Kit
TUCSON, Ariz., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Accelerate) today announced that the U.S. Food and Drug Administration has granted the de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. The blood culture kit is indicated for susceptibility testing of specific pathogenic bacteria commonly associated with bacteremia, the leading cause of sepsis....
Feb 23, 2017 04:19 pm ET
Accelerate Diagnostics to Report Preliminary Fourth Quarter and Full Year 2016 Results on February 27th
TUCSON, Ariz., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced it will report preliminary fourth-quarter and full year 2016 financial results on Monday, February 27th, 2017....
Nov 22, 2016 01:58 pm ET
Accelerate Diagnostics to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 30th
TUCSON, Ariz., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the Piper Jaffray 28th Annual Healthcare Conference in New York City, NY on Wednesday, November 30th at 2:00 PM EST....
Oct 21, 2016 05:45 pm ET
Accelerate Diagnostics to Report Third-Quarter 2016 Results on November 9th
TUCSON, Ariz., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will report third-quarter 2016 financial results on Wednesday, November 9, 2016....
Jul 22, 2016 08:15 am ET
Accelerate Diagnostics to Report Second-Quarter 2016 Results on August 8
TUCSON, Ariz., July 22, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will report second-quarter 2016 financial results on Monday, August 8th....
Jul 11, 2016 05:00 am ET
Accelerate Diagnostics Submits De Novo Request to FDA for Accelerate Pheno™ System and Accelerate PhenoTest™ BC kit
TUCSON, Ariz., July 11, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“Accelerate”) announced today the submission of a De Novo request for Evaluation of Automatic Class III Designation to the U.S. Food and Drug Administration (FDA) for its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood culture samples.  ...
Jun 14, 2016 07:57 pm ET
Accelerate Diagnostics Completes Clinical Data Collection, Will Present Data at the William Blair 36th Annual Growth Stock Conference
TUCSON, Ariz., June 14, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“Accelerate”) announced today the completion of clinical data collection intended for submission to the FDA in conjunction with its de novo 510k request for premarket clearance of the Accelerate Pheno™ system and Accelerate Pheno™ BC kit for positive blood cultures. An overview of the data collected will be included in the previously announced presentation at the William Blair 36th Annual Growth Stock Conference. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit were formerly referred to in generic ter...
Jun 07, 2016 07:06 pm ET
Accelerate Diagnostics to Present at the 36th Annual Growth Stock Conference
TUCSON, Ariz., June 07, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, the company’s president and chief executive officer, is scheduled to present to investors at the 36th Annual Growth Stock Conference hosted by William Blair & Company, L.L.C. on June 15, 2016 at 8:00 a.m. Central Time at the Four Seasons Hotel in Chicago, Illinois. The presentation will be accessible from the investor portal of the company’s website at http://ir.axdx.com....
Feb 11, 2016 09:31 am ET
Covered Call Alerts For Twitter, Akamai Technologies, Criteo SA, Accelerate Diagnostics and Peabody Energy Released By InvestorsObserver
CHICAGO, Feb. 11, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TWTR, AKAM, CRTO, AXDX and BTU.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.